1-benzoyl-3-2,3-dihydro-1H-inden-5-ylthiourea | 117174-80-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1-benzoyl-3-2,3-dihydro-1H-inden-5-ylthiourea
• 英文别名: N-[(5-Indanyl)carbamothioyl]benzamide；N-(2,3-dihydro-1H-inden-5-ylcarbamothioyl)benzamide
• CAS: 117174-80-8
• 化学式: C₁₇H₁₆N₂OS
• 分子量: 296.393
• InChiKey: FQBDJDUPSVHSLI-UHFFFAOYSA-N

物化性质

• 密度：
  1.301±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  73.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-benzoyl-3-2,3-dihydro-1H-inden-5-ylthiourea 在 sodium metabisulfite 、 溴 、 potassium hydroxide 、 sodium hydroxide 作用下， 以 乙二醇甲醚 、 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 2-(2,4-dimethoxyphenyl)-6,7-dihydro-5H-indeno[5,6-d]thiazole
  参考文献：
  名称：

  De novo tyrosinase inhibitor: 4-(6,7-Dihydro-5H-indeno[5,6-d]thiazol-2-yl)benzene-1,3-diol (MHY1556)

  摘要：

  In this study, we have synthesized and studied de novo tyrosinase inhibitor, MHY1556, which showed significantly better efficacy than other pre-existing tyrosinase inhibitors in vitro experiments. The IC50 value of MHY1556 was 0.50 mu M which was significantly lower than that of kojic acid ( IC50 = 53.95 mu M), which is a well-known tyrosinase inhibitor and was used as a positive control in this study. We predicted the tertiary structure of tyrosinase, simulated the docking with compound MHY1556 and confirmed that the compound strongly interacts with mushroom tyrosinase residues. Substitutions with a hydroxy group at both R1 and R3 of the phenyl ring indicated that these groups play a major role in the high binding affinity to tyrosinase, especially through the hydrogen bonding interaction of the hydroxyl group at R1 with GLY281. In addition, MHY1556 showed concentration-dependent inhibitory effects in melanin content assay where B16F10 melanoma cells were treated with alpha-melanocyte stimulating hormone (alpha-MSH), and also there is no significant cytotoxicity of this compound in cell viability assay conducted in B16F10 melanoma cells. The tyrosinase activity assay results with MHY1556 also support its potent inhibitory effects. Therefore, our data strongly suggest MHY1556 suppresses the melanogenesis via a tyrosinase inhibitory effect. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.029
• 作为产物：
  描述：

  苯甲酰氯 以 丙酮 为溶剂， 反应 1.33h， 生成 1-benzoyl-3-2,3-dihydro-1H-inden-5-ylthiourea
  参考文献：
  名称：

  De novo tyrosinase inhibitor: 4-(6,7-Dihydro-5H-indeno[5,6-d]thiazol-2-yl)benzene-1,3-diol (MHY1556)

  摘要：

  In this study, we have synthesized and studied de novo tyrosinase inhibitor, MHY1556, which showed significantly better efficacy than other pre-existing tyrosinase inhibitors in vitro experiments. The IC50 value of MHY1556 was 0.50 mu M which was significantly lower than that of kojic acid ( IC50 = 53.95 mu M), which is a well-known tyrosinase inhibitor and was used as a positive control in this study. We predicted the tertiary structure of tyrosinase, simulated the docking with compound MHY1556 and confirmed that the compound strongly interacts with mushroom tyrosinase residues. Substitutions with a hydroxy group at both R1 and R3 of the phenyl ring indicated that these groups play a major role in the high binding affinity to tyrosinase, especially through the hydrogen bonding interaction of the hydroxyl group at R1 with GLY281. In addition, MHY1556 showed concentration-dependent inhibitory effects in melanin content assay where B16F10 melanoma cells were treated with alpha-melanocyte stimulating hormone (alpha-MSH), and also there is no significant cytotoxicity of this compound in cell viability assay conducted in B16F10 melanoma cells. The tyrosinase activity assay results with MHY1556 also support its potent inhibitory effects. Therefore, our data strongly suggest MHY1556 suppresses the melanogenesis via a tyrosinase inhibitory effect. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.029

文献信息

• Improved Procedures for the Preparation of Cycloalkyl-, Arylalkyl-, and Arylthioureas
  作者：C. R. Rasmussen、F. J. Villani, Jr.、L. E. Weaner、B. E. Reynolds、A. R. Hood、L. R. Hecker、S. O. Nortey、A. Hanslin、M. J. Costanzo、E. T. Powell、A. J. Molinari

  DOI：10.1055/s-1988-27605

  日期：——

  An improved procedure for the preparation of arylthioureas consists of the reaction of benzoyl isothiocyanate with anilines in acetone and debenzoylation of the resultant N-aryl-N′-benzoylthioureas with 5% aqueous sodium hydroxide. Bicycloalkylthioureas and N-(arylalkyl)thioureas (e.g., 9H-9-fluorenylthiourea) are directly prepared from the corresponding isothiocyanates and ammonia.

  制备芳基硫脲的改进方法包括将苯甲酰异硫氰酸酯与苯胺在丙酮中反应，然后用5%氢氧化钠水溶液对生成的N-芳基-N'-苯甲酰硫脲进行去苯甲酰化。双环烷基硫脲和N-(芳烷基)硫脲（例如9H-9-芴基硫脲）可直接由相应的异硫氰酸酯与氨反应制备。
• EP2908843A1
  申请人：——

  公开号：EP2908843A1

  公开（公告）日：2015-08-26
• TREATING CANCER
  申请人：Agency for Science, Technology and Research

  公开号：EP2908843B1

  公开（公告）日：2019-09-04
• COMPOSITIONS AND METHODS FOR INHIBITING EZH2
  申请人：Chinnaiyan Arul M.

  公开号：US20110251216A1

  公开（公告）日：2011-10-13

  The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in cancer (e.g., prostate cancer, breast cancer, other solid tumors, multiple myeloma).
• METHOD OF TREATING CANCER
  申请人：Agency for Science, Technology and Research

  公开号：US20150258175A1

  公开（公告）日：2015-09-17

  The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.